entertainment -WSS

entertainment

author：knowledge 2025-09-06 07:48:44 - browse：88599

Fatty liver foregrounds arteries and veins surrounded by red blood cells — health coverage from STAT — Adobe

As drugmakers race to join the obesity drug market ignited by the approval of Wegovy and Zepbound, they’re not just competing on their drugs’ weight loss effects. They’re also competing on their products’ ability to treat a severe form of liver disease.

A new update of the STAT Obesity Drug Tracker shows that at least 23 — about one-fifth — of the 105 obesity treatments in development or on the market are also being investigated for metabolic dysfunction-associated steatohepatitis, the fatty liver disease known as MASH (and previously called NASH).

In this update, STAT has added a category — “other diseases investigated” — to show conditions beyond obesity for which a compound is being studied. Type 2 diabetes is the most common – it’s long been linked to obesity, and the latest GLP-1 treatments like Wegovy and Zepbound were initially developed as diabetes drugs. But behind diabetes, the next most common disease under investigation for obesity candidates is MASH.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Oak trusses raised to roof of fire

WSS

FDA has safety concerns on CRISPR

FDA has safety concerns on CRISPR

Insurance companies sue energy corporation after it was blamed for helping start Colorado wildfire

NIH fellows want a pay raise. Will that mean less money for grants?

Iowa House, Senate pass 6

CDC recommends rationing of RSV shot due to shortages

hotspot

entertainment

Wikipedia

State Dept. review finds Biden bears some blame for Afghanistan failures

Living with Fabry disease, a condition that causes chronic pain

Heart attack and stroke risk calculators need revising

Senate panel to vote on hospitals, PBMs, prisoner care

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

First Opinion Podcast: How to protect health care in times of war

Jerome Adams on the need for new antivirals for Covid

Living with Fabry disease, a condition that causes chronic pain

Supreme Court strikes down use of affirmative action

Eli Lilly to pay $200M for Beam’s stake in gene

entertainment

Why 40% Americans with Parkinson’s don’t see a neurologist

CDC recommends rationing of RSV shot due to shortages

Eli Lilly to pay $200M for Beam’s stake in gene

Readout Newsletter: XBI biotech index, Akero Therapeutics

Emergency medicine has repudiated 'excited delirium.' Now what?

Biden launches a new push to limit health care costs

knowledge

explore

leisure time

explore